eli lilly retatrutide study Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces

Was this ever an issue in your career

In preclinical models with an acute diet-induced liver injury model due to a single high-dose fructose binge in mice, as well as a chronic mouse feeding model incorporating fructose intended to mirror early MASLD with features of steatohepatitis, Retatrutide reduced the expression of hepatic inflammation markers chemokine ligand-1 (Cxcl-1), serum amyloid A1 (Saa-1), and serum amyloid A2 (Saa-2) (53)

When these factors are addressed first, GLP-1 therapy becomes part of a coordinated metabolic strategy rather than a stand-alone solution

Is your appetite truly out of control

While lower prices for state Medicaid programs could help alleviate cost concerns for states and result in expanded coverage of obesity drugs, how the new lower costs compare to the net prices state Medicaid programs currently pay and how states will respond amid tightening budget conditions remain unclear

Across pivotal Phase 3 trials, mean weight loss has scaled with the number of receptors a compound engages: semaglu tide (single agonist) at 14.9%, tirzepatide (dual agonist) at 22.5%, and retatrutide (triple agonist) at 28.3% over 80 weeks